Wire · opportunities
Nutshell Therapeutics wins FDA IND clearance for NRF2 degrader NTS231
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 September 2026 · Fusion42 review
Nutshell Therapeutics received FDA clearance for an investigational new drug application for NTS231, a novel NRF2 degrader targeting treatment-resistant cancers, enabling clinical development in the US. The drug was discovered using an AI-driven platform and shows promising preclinical efficacy against multiple cancer types with NRF2 pathway alterations.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 25 Sep 2026 and 29 Sep 2026.
◆ ◆ The Wire takeaway
You have a new opening to test AI-derived cancer drugs in the US market, as FDA IND clearance removes a major barrier for NRF2-targeted therapies. This clearance underscores the rising viability of AI platforms in accelerating drug discovery against tough cancer targets.
◆ Coverage
2 sources · first reported 25 Sep 2026 · latest 29 Sep 2026
◆ Related on Wire
◆ Topics